| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
BridgeBio Oncology Therapeutics, Inc.$8.32
-0.7 (-7.7%)
D 33Pipeline Score Overvalued Biotech · Clinical
Market Cap
684.92 M
EPS
-527.59
P/E Ratio
-
Value Trade
1.40 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
39.80 M
Operating CF
-35.92 M
Total Assets
417.65 M
Total Liabilities
45.37 M
Equity
372.28 M
D/E Ratio
12,345
2.15 %
Week
-8.95 %
1 Month
-14.5 %
3 Month
-29.8 %
6 Month
-14.76 %
5 Year
-14.76 %
All Time
Cash Data
Cash Position
252.27 M
Monthly Burn
11.97 M
Runway
19.4 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
389.51 K
52 Week Range
7.60 - 14.87
% held by Insiders
45.8 %
% held by Institutions
51.96 %
Enterprise Value
435.28 M
Total Shares
80.03 M
Short %
9.08 %
Float Shares
42.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BridgeBio Oncology Therapeutics, Inc.
61Total events
5Upcoming
17Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 5
Event history 56
May 12, 2026
Apr 22, 2026
◆Poster PresentationBBO-11818Presentation
Poster presentation on BBO-11818 at AACR 2026
KRAS-mutant solid tumorssource ↗
Apr 21, 2026
◆Oral PresentationBBO-10203Presentation
Oral presentation on BBO-10203 at AACR 2026
HER2+ breast cancer, HR+/HER2- breast cancer, KRAS-mutant colorectal cancer, KRAS-mutant non-small cell lung cancersource ↗
Apr 20, 2026
◆Management ChangeCorporate
Appointment of Pedro J. Beltran, PhD as CEO, Idan Elmelech as COO, and Neil Kumar, PhD as Executive Chairman
Apr 2026
▲Trial InitiationBBO-8520Trial
Internal combination study of BBO-8520 with BBO-10203 opened
KRAS G12C non-small cell lung cancersource ↗
Q2 2026
◆Topline ReadoutBBO-8520Clinical Data
Updated clinical data expected for BBO-8520
KRASG12C NSCLCsource ↗
Q2 2026
◆Topline ReadoutBBO-11818Clinical Data
Updated clinical data expected for BBO-11818
advanced solid tumorssource ↗
Q2 2026
◆Topline ReadoutBBO-10203Clinical Data
Updated clinical data expected for BBO-10203
advanced solid tumorssource ↗
Q2 2026
◆Trial InitiationBBO-11818Trial
Internal combination trial of BBO-11818 with BBO-10203 anticipated to open
advanced solid tumorssource ↗
Q2 2026
◆Trial InitiationBBO-10203Trial
Internal combination trials of BBO-10203 with BBO-8520 and BBO-11818 anticipated to open
advanced solid tumorssource ↗
Mar 6, 2026
▲PublicationBBO-11818Presentation
Publication of preclinical data for BBO-11818 in Cancer Discovery
KRAS mutant solid tumorssource ↗
Drug Pipeline Intelligence
D33
Pipeline Score $123M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 43%
Micro Cap (rank 520 of 911)
Percentile RankBridgeBio Oncology Therapeutics, Inc. faces pipeline headwinds (33/100), with $463M risk-adjusted pipeline value, led by BBO-11818 in Non-Small Cell Lung Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBO-11818 Small molecule | Non-Small Cell Lung Cancer | Phase 1 | NCT06917079 | 5% | $196M | RECRUITING | 665 | VERY_FAST | D (35) | Sep 1, 2029 | ELEVATED_RISK | MEDIUM Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BBO-8520 | non-small cell lung cancer (NSCLC) | Phase 1 | 2026-05-12 | objective response rate: 65%; six month progression free survival: 68%; patients remaining on treatment: 83% Read More | BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress Read More | |
BBO-8520 | non-small cell lung cancer (NSCLC) | Phase 1 | 2026-05-12 | objective response rate: 65%; six month progression free survival: 68%; patients remaining on treatment: 83% Read More | BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress Read More | |
BBO-8520 | non-small cell lung cancer (NSCLC) | Phase 1 | 2026-05-12 | objective response rate: 65%; six month progression free survival: 68%; patients remaining on treatment: 83% Read More | BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BBOT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BBOT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 12, 2026
BridgeBio Oncology Therapeutics (BBOT) announced the award of inducement grants to a new employee as part of its 2025 Inducement Plan. The grants include non-qualified stock options for 32,675 shares at an exercise price of $7.66, vesting over time contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and showcases BBOT's commitment to attracting talent.
Read more →BBOTBBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported its Q1 2026 financial results, highlighting progress in its RAS-pathway inhibitor programs. Notable developments include promising preliminary data for BBO-8520 and BBO-11818, with clinical readouts expected later in 2026. The company maintains a strong cash position, projected to support operations through 2028.
Read more →BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics (BBOT) has announced the awarding of inducement grants to a new employee as part of its 2025 Inducement Plan. The grants consist of non-qualified stock options for 32,675 shares at an exercise price of $7.66. These options will vest over a four-year period, contingent on the employee's continued service. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects BBOT's commitment to attracting talent.
Read more →BBOT▼ -6.2%on this news
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman Pedro J. Beltran, PhD, a seasoned executive who pr
BBOT has announced the appointments of Pedro J. Beltran, PhD, as the new Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman. This leadership change is intended to guide the company as it progresses into a new phase of development with its clinical assets moving towards pivotal trials for RAS and PI3K malignancies. The Board of Directors believes that these appointments reflect BBOT's dedication to improving patient outcomes and executing its strategic goals effectively.
Read more →BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 13, 2026
BridgeBio Oncology Therapeutics (BBOT) has awarded inducement grants to a new employee as part of its 2025 Inducement Plan. The grants include non-qualified stock options for 32,675 shares at an exercise price of $8.40, vesting over time contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects BBOT's strategy to enhance its workforce.
Read more →BBOT▼ -6.3%on this news
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced multiple presentations at the AACR Annual Meeting 2026 in San Diego. The presentations will focus on their innovative therapies BBO-10203 and BBO-11818, targeting RAS-pathway malignancies. BBO-11818 is currently in a Phase 1 trial for KRAS-mutant solid tumors, while BBO-10203 is being evaluated for HER2+ breast cancer and other indications.
Read more →BBOTBBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
BBOT has published preclinical data on BBO-11818, a selective panKRAS inhibitor, demonstrating its efficacy against KRAS mutant cancers. The compound shows promising tumor growth inhibition and potential for combination therapies. Preliminary data from the ongoing Phase 1 KONQUER-101 trial indicates encouraging anti-tumor activity, with further updates expected in 2026.
Read more →BBOTBBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small mol
BBOT has released its fourth quarter and full year 2025 financial results, highlighting a successful debut as a publicly traded oncology company. The company is advancing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Encouraging preliminary data has been reported for these programs, with significant clinical readouts expected in late 2026. Furthermore, BBOT's robust cash position is projected to fund operations into 2028, supporting ongoing development efforts.
Read more →BBOT▼ -5.1%on this news
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 11, 2026
BridgeBio Oncology Therapeutics (BBOT) announced the awarding of inducement grants to two new employees as part of its 2025 Inducement Plan. The grants, which include non-qualified stock options for 65,350 shares, are intended to incentivize the new hires. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects BBOT's commitment to enhancing its workforce.
Read more →BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - January 13, 2026
BridgeBio Oncology Therapeutics (BBOT) announced the awarding of inducement grants under its 2025 Inducement Plan. The grants were made to a new employee hired in December 2025, consisting of stock options for 129,090 shares at an exercise price of $13.19. These awards are part of BBOT's strategy to attract talent and were approved by the board's compensation committee.
Read more →BBOTBBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3K Pipeline Programs BBO-8520 monotherapy in patients with KR AS G12C non-small cell lung cancer (NSCLC) showed a
BridgeBio Oncology Therapeutics (BBOT) announced positive preliminary data for its three RAS and PI3K pipeline programs, highlighting the potential of BBO-8520, BBO-11818, and BBO-10203. The data shows encouraging safety profiles and anti-tumor activity, particularly for BBO-8520, which may serve as a significant combination therapy with pembrolizumab. BBOT aims to address unmet needs in treating KRASG12C mutant NSCLC and plans to continue developing these therapies through advanced clinical trials.
Read more →BBOTBBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced late-breaking preclinical data on BBO-10203, a novel RAS:PI3Kα breaker, at the San Antonio Breast Cancer Symposium. The data suggests that BBO-10203 can inhibit RAS-driven PI3Kα-AKT signaling without causing hyperglycemia. Additionally, the company will present a trial in progress poster for the Phase 1 BREAKER-101 study, which evaluates BBO-10203 in various cancer types.
Read more →BBOTBBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3K and a syne
BridgeBio Oncology Therapeutics, Inc. (BBOT) has released its third-quarter financial results for 2025, highlighting its recent Nasdaq debut and the appointment of Uneek Mehra as Chief Financial Officer. The company is advancing a promising pipeline targeting RAS and PI3K malignancies, with three clinical assets progressing toward important data readouts in 2026. Despite a reported net loss of $44,757, BBOT's financial position is projected to sustain operations until 2028. However, elevated operational expenses and the accumulated deficit signal ongoing financial hurdles.
Read more →BBOTINDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS TheRas, Inc. Page Unaudited Condensed Financial Statements: Unaudited Condensed Balance Sheets as of
TheRas, Inc. has released its unaudited condensed financial statements for the period ending June 30, 2025. The company reported a significant net loss of $28,435 for the quarter, an increase from the previous year. Assets totaled $151,253, a decrease from the end of 2024. Operating expenses also climbed, largely driven by higher research and development costs. The stockholders' deficit continued to grow, raising concerns about the company’s financial health.
Read more →BBOTHelix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics Gross proceeds of approximately $120 million from trust acc
Helix Acquisition Corp. II announced it has retained over 60% of its trust account following shareholder redemptions in connection with its business combination with BridgeBio Oncology Therapeutics. This retention results in approximately $120 million remaining, contributing to total expected proceeds of around $382 million from the merger. The closing of this transaction is set to proceed quickly, pending the satisfaction of closing conditions.
Read more →BBOTHelix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination Extraordinary General Meeting of Helix Shareholders Scheduled for
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced that their registration statement for a proposed business combination has been declared effective by the SEC. This event paves the way for an extraordinary general meeting of Helix shareholders, scheduled for August 4, 2025, to discuss the merger. Upon completion of this merger, the company will be renamed BridgeBio Oncology Therapeutics, aiming to advance a new pipeline of innovative cancer therapeutics.
Read more →BBOTBridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3K -Targeting Medicines Tota
BridgeBio Oncology Therapeutics (BBOT) has entered a definitive business combination agreement with Helix Acquisition Corp. II to create a publicly listed biotechnology company focused on RAS and PI3K-targeting medicines. The transaction is expected to provide BBOT with approximately $550 million in cash to advance its clinical programs. Key lead programs include treatments targeting KRAS mutations in various cancer types. The merger is anticipated to be completed in the third quarter of 2025, pending shareholder approval.
Read more →BBOTHELIX ACQUISITION CORP. II INDEX TO FINANCIAL STATEMENT Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F- 1 Report of Independent Registered Public Acc
Helix Acquisition Corp. II has completed its Initial Public Offering on February 13, 2024, generating gross proceeds of $184 million. The independent auditor confirmed that the financial statement accurately reflects the company's financial position, with a total asset value of $186.5 million. Although the company has not yet commenced operations, it plans to pursue business combinations, particularly in the healthcare sector. The cash from the IPO is secured in a trust account until a business combination occurs.
Read more →BBOTHelix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering Boston, Massachusetts
Helix Acquisition Corp. II has announced the pricing of its upsized initial public offering at $160 million, with 16 million Class A ordinary shares priced at $10.00 each. The shares will be listed on The Nasdaq under the ticker symbol 'HLXB' starting February 9, 2024. The company, which targets opportunities in the healthcare sector, also has provisions for underwriters to purchase additional shares to cover over-allotments. The IPO's completion is anticipated on February 13, 2024, but is subject to various conditions.
Read more →Competitive Position
How BBOT ranks across every disease it competes inCompetitive Position is a premium feature
See how BBOT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial